The effect of Quil A adjuvant on the course of experimental Fasciola hepatica infection in sheep

Effects of different Fasciola hepatica recombinant proteins on the biochemical and serological responses of experimentally infected sheep

“…Their values in our trial are different; the γGT rose only between the 8th and 9th weeks and the LDH values fell continuously until the end of the trial (not characteristic for liver damage). During the same parasitosis Haçarız et al (11) established an increase in this enzyme between the 13th and 23rd weeks, with a maximum in the 19th week, which is different from our data (Figure 4). The activity of γGT in the adjuvant-treated animals in our experiments did not change too much in comparison to the value of the controls ( Figure 3, the first measurement with an exception in the 2nd measurement), but this evaluation cannot be explained by an adoptive or antiparasitic reaction.…”

“…The lambs injected with the adjuvant did not show different features, which was not the case in the experiments conducted by Haçarız et al (11), who established a maximal increase in this enzyme during the 13th week.…”

“…This adjuvant, initially refined by Dalsgaard (9) and containing triterpene glycosides, was estimated by Kensil et al (10) and has subsequently been subjected to intensive investigations. Its efficacy was followed in lambs with F. hepatica parasitosis by Haçarız et al (11), who established a maximum response during the 8-10-week period after a sharp start. Our observations in this respect generally coincide with those of these authors, but the maximum value is somewhat earlier than 6-8 weeks.…”

“…Haçarız et al (11) was investigating 3 adjuvants and came to the conclusion that the Quil A adjuvant could be useful in anti-Fasciola hepatica vaccines, because it induces a strong elevation of the immune response after such an infection. It can be seen in Figures 1c and 1d of our results that in the same week after challenge (2nd week) the response to CL1 in adjuvant-treated animals is even higher than that in the group without the adjuvant.…”

Selection of Adjuvants for Enhanced Vaccine Potency

“…They have been proven to be very effective in enhancing the immunogenicity of various vaccines, including Aβ(1-15) in mice [240]; foot-and -mouth disease virus (FMDV) antigen in mice [241]; L1 and A33 proteins in mice [242]; vaccinia virus proteins in monkeys [242]; parasitic antigens in sheeps [243]; keyhole limpet hemocyanin (KLH) conjugate antigens [238,244,245]. The effect is often toward a Th1-type response in comparison with aluminum-based vaccine such as Aβ (1-15), PADRE-Aβ(1-15)-MAP) [240], L1 and A33 proteins in mice [242], parasitic antigen (Fasciola hepatica) in sheeps [243].…”